Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Sudden Sensorineural Hearing Loss

Xiao-Feng Qiao\textsuperscript{a} Xin Li\textsuperscript{b} Guo-Ping Wang\textsuperscript{a} Yin-Huan Bai\textsuperscript{a} Wei Zheng\textsuperscript{a}

Tong-Li Li\textsuperscript{a}

\textsuperscript{a}Department of Otorhinolaryngology, Shanxi Provincial People’s Hospital Affiliated to Shanxi Medical University, Taiyuan, China; \textsuperscript{b}Department of Surgery, Children’s Hospital of Shanxi Province, Taiyuan, China

Significance of the Study

- This study shows that the peripheral blood neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are associated with the outcome and prognosis of sudden sensorineural hearing loss (SSNHL). A higher NLR in patients with SSNHL suggests local inflammation, while a higher PLR suggests pathological damage of endothelial cells. The detection of NLR and PLR can be used as the basis for individualized treatment of SSNHL as it is convenient, reliable, and economical.

Keywords

Sudden sensorineural hearing loss · Neutrophils · Lymphocytes · Platelets · Ratios

Abstract

Objective: Sudden sensorineural hearing loss (SSNHL) is a common acute disease with an incidence of 0.5–2/10,000. This study aimed to determine whether the neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR) could be indicators for SSNHL. Methods: A total of 60 confirmed cases of SSNHL and 60 healthy volunteers were included in this study. Peripheral blood NLRs and PLRs were compared between these groups. The SSNHL patients were divided into two groups, according to therapeutic effect: an effective group and an ineffective group. Peripheral blood NLRs and PLRs before and after treatment were compared between these two groups. Results: The average NLRs and PLRs of these patients were both significantly higher than in controls. The average NLRs and PLRs of the ineffective group were both significantly higher than those of the effective group. Conclusion: Peripheral blood NLR and PLR could be used as a convenient, reliable, and cost-effective indicator to predict the prognosis of SSNHL.

Introduction

Sudden sensorineural hearing loss (SSNHL) is a common acute disease with an incidence of 0.5–2/10,000 [1, 2]. Many causes have been proposed; these include viral infection, vascular disturbance, microcirculatory failure, and immune mediation, but none of these are supported by definitive evidence [3–5]. Recent etiological research on SSNHL has focused on chronic inflammation [6]. Bac-
teria- or virus-induced chronic inflammation may cause microvascular injuries and atherosclerosis, raising the risks of cochlear ischemia [7]. However, cochlear ischemic alteration is just one potential pathological change of SSNHL with a vascular cause. Chronic inflammation can also induce corresponding endocochlear immune responses, further leading to cochlear injuries [3]. Researchers in cardiovascular diseases have used the neutrophil-to-lymphocyte ratio (NLR) in peripheral blood as a marker for cardiovascular diseases, and it may serve as a useful predictor of development of cardiovascular disease. Furthermore, the platelet-to-lymphocyte ratio (PLR) has been closely correlated with peripheral arterial occlusion diseases such as arteriosclerosis and arterial thrombosis [8]. Hence, elevation of peripheral NLR and PLR indicates the occurrence of vascular endothelial injury, atherosclerosis, and local microartery inflammation. On this basis, we hypothesized that peripheral NLR and PLR can also be used to predict the metastasis/development of SSNHL and applied as markers to easily measure prognosis. In the present study, we aimed to investigate the relationship of SSNHL with NLR and PLR, in an attempt to validate our hypothesis.

Materials and Methods

Clinical Data
A total of 60 SSNHL patients treated at Shanxi Provincial People’s Hospital between December 2015 and December 2016 (average age: 45.62 ± 13.16 years; male: 28; female: 32), according to the Sudden Hearing Loss Diagnosis and Treatment Guidelines of the Chinese Medical Association [9], were included in the study. In addition, 60 healthy subjects were assigned as the control group (average age: 49.62 ± 10.66 years; male: 31; female: 29). The inclusion criteria were as follows: no history of steroid treatment, blood abnormalities, coronary diseases, acute or chronic kidney failure, chronic liver disease, lung disease, infectious diseases (e.g., syphilis), immunological diseases, and any otological diseases (e.g., chronic otitis, otosclerosis, history of ear trauma, and Meniere’s disease).

Methods
Blood specimens were examined before the treatment. Based on medical history and test results, unqualified cases were excluded, while the included cases were assigned to the same therapeutic scheme.

Peripheral Blood Laboratory Examination
Peripheral blood was collected from all included subjects before treatment and 15 days after treatment, followed by routine blood cell analysis. The sample collection was done between 7 and 8 a.m. and the subjects were in a fasting state. The absolute counts of neutrophils, lymphocytes, and platelets in peripheral blood were obtained and the NLR and PLR of each case were calculated.

Table 1. Peripheral blood data in patients and controls

| Parameter                  | Patients (n = 60) | Controls (n = 60) | p value |
|----------------------------|------------------|------------------|---------|
| WBC count, ×10⁹/L          | 8.38±1.33        | 5.24±1.39        | 0.001   |
| Neutrophil count, ×10⁹/L   | 7.23±1.41        | 3.57±1.02        | 0.000   |
| Platelet count, ×10⁹/L     | 263.90±47.90     | 201.45±41.11     | 0.356   |
| Lymphocyte count, ×10⁹/L   | 2.20±1.00        | 1.88±0.57        | 0.022   |
| NLR                       | 3.96±1.92        | 2.33±0.97        | 0.000   |
| PLR                       | 145.69±74.66     | 117.30±44.06     | 0.003   |
| Age                       | 45.62±13.16      | 49.62±10.66      | 0.081   |

NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; WBC, white blood cell.

Detection of Pure-Tone Hearing
For the 60 patients, pure-tone hearing was measured before treatment and 15 days after treatment. Specifically, the bone conduction threshold and air conduction threshold at 250, 500, 1,000, 2,000, 4,000, and 8,000 Hz were recorded. According to the therapeutic effect evaluation standards of the Sudden Hearing Loss Diagnosis and Treatment Guidelines of the Chinese Medical Association, patients who achieved “cured,” “markedly effective,” and “effective” outcomes were classified as the “effective group,” and patients who achieved “ineffective” outcome were classified as the “ineffective group.”

Treatment Regimen
All 60 patients were treated with the following regimen: intravenous injection of 10 mg of dexamethasone for 3 consecutive days and intravenous drip injection of 70 mg of ginkgo biloba extract (Ginaton) for 15 consecutive days.

Statistical Methods
The average peripheral NLR and PLR were tested via t test for the test group versus control group and the effective group versus ineffective group on SPSS 20. The NLR and pure-tone hearing thresholds were examined on the straight line correlation analysis.

Results
The white blood cell (WBC) count, neutrophil count, lymphocyte count, NLR, and PLR of SSNHL patients before the treatment were all significantly higher than those of the controls (Table 1).

The lymphocyte count and NLR were both significantly different before treatment in the effective group compared to the ineffective group (p < 0.05). After treatment,
Blood Cell Ratios in Patients with Sudden Sensorineural Hearing Loss

Table 2. Peripheral blood data in the effective and ineffective subgroups

| Parameter                  | Before treatment | After treatment |
|----------------------------|------------------|-----------------|
|                            | effective (n = 48)| ineffective (n = 12) | p value |
|                            | effective (n = 48)| ineffective (n = 12) | p value |
| WBC count, ×10^9/L         | 8.31±1.32        | 8.65±1.42       | 0.124   |
| Neutrophil count, ×10^9/L  | 7.26±1.41        | 7.10±1.48       | 0.245   |
| Platelet count, ×10^9/L    | 256.15±50.16     | 226.08±54.08    | 0.350   |
| Lymphocyte count, ×10^9/L  | 2.62±1.22        | 1.54±0.56       | 0.002   |
| NLR                        | 3.39±1.71        | 5.21±2.27       | 0.031   |
| PLR                        | 132.81±60.89     | 154.23±63.85    | 0.258   |
|                            | 6.24±1.06        | 8.74±1.20       | 0.018   |
|                            | 6.68±1.27        | 7.16±0.99       | 0.157   |
|                            | 199±50.02        | 212±34.87       | 0.351   |
|                            | 2.91±1.59        | 1.45±1.44       | 0.285   |
|                            | 2.45±1.45        | 5.03±1.68       | 0.000   |
|                            | 121.02±46.98     | 158.31±52.38    | 0.025   |

NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; WBC, white blood cell.

Table 3. Correlation analysis between NLR and hearing thresholds before and after treatment in the SSNHL patients

| Subgroup     | Before treatment | After treatment |
|--------------|------------------|-----------------|
|              | NLR              | hearing threshold | r       | NLR              | hearing threshold | r       |
| Effective    | 3.39±1.71        | 48.62±16.62     | 0.45    | 2.45±1.45        | 22.81±11.80      | 0.57    |
| Ineffective  | 5.21±2.27        | 60.42±11.77     | 0.64    | 5.03±1.68        | 57.50±13.06      | 0.54    |

NLR, neutrophil-to-lymphocyte ratio; SSNHL, sudden sensorineural hearing loss.

Table 4. Correlation analysis between NLR and age before and after treatment in the SSNHL patients

| Subgroup     | Before treatment | After treatment |
|--------------|------------------|-----------------|
|              | NLR              | age             | r       | NLR              | age             | r       |
| Effective    | 3.39±1.71        | 45.86±13.65     | 0.19    | 2.45±1.45        | 45.86±13.65     | 0.17    |
| Ineffective  | 5.21±2.27        | 45.10±11.29     | 0.14    | 5.03±1.68        | 45.10±11.29     | 0.11    |

NLR, neutrophil-to-lymphocyte ratio; SSNHL, sudden sensorineural hearing loss.

Discussion

SSNHL is a common acute disease in otolaryngology that mainly manifests as sudden acute deafness. SSNHL is defined as sudden hearing loss without definite cause within 72 h, with a hearing drop of ≥20 dB in at least two adjacent frequencies [9]. However, the precise pathophysiological mechanisms underlying SSNHL remain unknown and may be induced by local and systemic factors. A number of hypotheses have explained the cause of SSNHL, such as immune reactions, microcirculatory disturbance, infection, infectious disease, and tumors. Many researchers have suggested viral etiologies, but antiviral treatment has not achieved a satisfactory effect. To date,
there are no specific reports on serological characteristics. Merchant et al. [4] studied the temporal bone histopathology of 15 deaf ears and found viral particles without microscopy; thus, no direct cochlear evidence has been found for viral infection. No immune- or autoimmune-mediated injuries have been reported [10], indicating a lack of support for possible immune etiologies. The thrombosis hypothesis regarding the pathogenesis of SSNHL should be questioned because there was no difference in incidence rate between males and females [11]. Existing etiological research on SSNHL has focused on chronic inflammation. It has been believed that bacteria- or virus-induced chronic inflammation could cause microvascular injury, vascular endothelial dysfunction, and atherosclerosis, leading to an increased risk of cochlear ischemia [7, 12, 13]. Furthermore, susceptibility to genetic thrombosis or cardiovascular risk factors would further aggravate the risk of cochlear ischemia [14, 15]. The NLR in peripheral blood has not only been proved to be one of the definitive markers of chronic inflammation in the cardiovascular system, it is also a reliable predictor of functional recovery after vascular disease. Furthermore, this index is easy to measure in clinical practice [16–18]. Moreover, the PLR is closely correlated with peripheral occlusion diseases such as arteriosclerosis and arterial thrombosis [8]. Hence, the elevation of peripheral NLR and PLR indicates the occurrence of atherosclerosis and local microartery inflammation [19–23]. In the present study, we aimed to investigate the relationship of SSNHL with NLR and PLR.

The WBC count, neutrophil count, lymphocyte count, NLR, and PLR of SSNHL patients before treatment were all significantly higher than those of the controls. The lymphocyte count and NLR before treatment in the effective group were both significantly lower than those in the ineffective group. After treatment, WBC count, NLR, and PLR were all significantly different between groups, while NLR was positively correlated with hearing thresholds in SSNHL patients both before and after treatment. This indicates that the NLR can be considered for use as a predictor of SSNHL.

A higher peripheral NLR suggests the occurrence of local microartery vascular inflammation, which involves the labyrinthine artery. However, the NLR before treatment was higher in the ineffective group than in the effective group, indicating that the cochlear microvascular local inflammation was more severe. Thus, as for treatment, systemically or locally used glucocorticoid exerts an anti-inflammatory effect and reduces the microvascular local inflammatory reaction, which involves the labyrinthine artery [24]. This indicates the achievement of a satisfactory therapeutic effect [9]. A larger PLR indicates that a patient with SSNHL may be suffering from pathological injury to peripheral vascular endothelial cells that involves the labyrinthine artery. On this basis, antioxidant drugs and antiplatelet aggregative drugs may be beneficial. As for the ineffective group, the PLR after treatment increased relative to the effective group, suggesting that the more severe injuries to vascular endothelial cells and the formation of atherosclerotic plaques accounted for the bad prognosis in these ineffective patients, which should be taken into consideration for therapy.

**Conclusion**

The NLR can be considered for use as a marker for prognosis and the development of SSNHL, while the NLR and the PLR can be considered for use as a basis for personalized therapy.

**References**

1. Stachler RJ, Chandrasekhar SS, Archer SM, Rosenfeld RM, Schwartz SR, Barrs DM, et al.; American Academy of Otolaryngology-Head and Neck Surgery. Clinical practice guideline: sudden hearing loss. Otolaryngol Head Neck Surg. 2012 Mar;146(3 Suppl):S1–35.

2. Schreiber BE, Agrup C, Haskard DO, Luxon LM. Sudden deafness. Lan-cet. 2010 Apr;375(9721):1203–11.

3. Masuda M, Kanzaki S, Minami S, Kikuchi J, Kanzaki J, Sato H, et al. Correlations of inflammatory biomarkers with the onset and prognosis of idiopathic sudden sensorineural hearing loss. Otol Neurotol. 2012 Sep;33(7):1142–50.

4. Merchant SN, Durand ML, Adams JC. Sudden deafness: is it viral? Otolaryngol Relat Spec. 2008;70(1):52–60.

5. Hoffman M, Blum A, Baruch R, Kaplan E, Benjamin M. Leukocytes and coronary heart disease. Atherosclerosis. 2004 Jan;172(1):1–6.

6. Gary T, Pichler M, Belaj K, Hafner F, Gerger A, Froehlich H, et al. Platelet-to-lymphocyte ratio: a novel marker for critical limb ischemia in peripheral arterial occlusive disease patients. PLoS One. 2013 Jul;8(7):e67688.

7. Hoffman M, Blum A, Baruch R, Kaplan E, Benjamin M. Leukocytes and coronary heart disease. Atherosclerosis. 2004 Jan;172(1):1–6.
Blood Cell Ratios in Patients with Sudden Sensorineural Hearing Loss

10 Toubi E, Ben-David J, Kessel A, Halas K, Sabo E, Luntz M. Immune-mediated disorders associated with idiopathic sudden sensorineural hearing loss. *Ann Otol Rhinol Laryngol*. 2004 Jun;113(6):445–9.

11 Weng SF, Chen YS, Hsu CJ, Tseng FY. Clinical features of sudden sensorineural hearing loss in diabetic patients. *Laryngoscope*. 2005 Sep;115(9):1676–80.

12 Ciccone MM, Cortese F, Pinto M, Di Teo C, Fornarelli F, Gesualdo M, et al. Endothelial function and cardiovascular risk in patients with idiopathic sudden sensorineural hearing loss. *Atherosclerosis*. 2012 Dec;225(2):511–6.

13 Capaccio P, Cuccarini V, Ottaviani F, Fracciolla NS, Bossi A, Pignataro L. Prothrombotic gene mutations in patients with sudden sensorineural hearing loss and cardiovascular thrombotic disease. *Ann Otol Rhinol Laryngol*. 2009 Mar;118(3):205–10.

14 Weng SF, Chen YS, Liu TC, Hsu CJ, Tseng FY. Prognostic factors of sudden sensorineural hearing loss in diabetic patients. *Diabetes Care*. 2004 Oct;27(10):2560–1.

15 Rudack C, Langer C, Stoll W, Rust S, Walter M. Vascular risk factors in sudden hearing loss. *Thromb Haemost*. 2006 Mar;95(3):454–61.

16 Nacar AB, Erayman A, Kurt M, Buyukkaya E, Karakaş MF, Akcay AB, et al. The relationship between coronary collateral circulation and neutrophil/lymphocyte ratio in patients with coronary chronic total occlusion. *Med Princ Pract*. 2015;24(1):65–9.

17 Lattanzi S, Cagnetti C, Rinaldi C, Angelocola S, Provinciali L, Silvestrini M. Neutrophil-to-lymphocyte ratio improves outcome prediction of acute intracerebral hemorrhage. *J Neurol Sci*. 2018 Apr;387:98–102.

18 Lattanzi S, Cagnetti C, Provinciali L, Silvestrini M. Neutrophil-to-lymphocyte ratio and neurological deterioration following acute cerebral hemorrhage. *Oncotarget*. 2017 Feb;8(34):57489–94.

19 Koçak HE, Elbistanlı MS, Acipayam H, Alarakas WME, Kural MN, Kayhan FT. Are neutrophil/lymphocyte and platelet/lymphocyte ratios related with formation of sudden hearing loss and its prognosis? *Eur Ann Otorhinolaryngol Head Neck Dis*. 2017 Dec;134(6):383–6.

20 Lee JS, Hong SK, Kim DH, Lee JH, Lee HJ, Park B, et al. The neutrophil-to-lymphocyte ratio in children with sudden sensorineural hearing loss: a retrospective study. *Acta Otolaryngol*. 2017 Jan;137(1):35–8.

21 Buluşcu S, Dikilitaş B, Arslan IB, Çakurova I. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in pediatric patients with idiopathic sudden hearing loss. *J Int Adv Otol*. 2017 Aug;13(2):217–20.

22 Park YA, Kong TH, Seo YJ. A sustained increase of plasma fibrinogen in sudden sensorineural hearing loss predicts worse outcome independently. *Am J Otolaryngol*. 2017 Jul-Aug;38(4):484–7.

23 Seo YJ, Jeong JH, Choi JY, Moon IS. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio: novel markers for diagnosis and prognosis in patients with idiopathic sudden sensorineural hearing loss. *Dis Markers*. 2014;2014:702807.

24 Makinae K, et al. Comparison of intratympanic and intravenous dexamethasone treatment on sudden sensorineural hearing loss with diabetes. *Otol Neurotol*. 2006 Aug;27(5):604–8.